XCORPOREAL INC

XCORPOREAL INC

OOTC:XCRP
0.00
USD
+0.00
(+900.00%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Victor Gura
Full Time Employees
24
Sector
Health technology
Industry
Medical specialties
Address
80 Empire Drive Lake Forest CA United States 92630
IPO Date
Feb 29, 2000
Business
Xcorporeal, Inc. Xcorporeal, Inc. (XCRP) operates as a shell company in the process of liquidation and dissolution under a plan adopted by its board of directors on February 4, 2010, with all assets transferred to the Xcorporeal, Inc. Liquidating Trust managed by XCRLT, LLC. Previously, the medical device company, founded in 2001 and headquartered at 80 Empire Drive, Lake Forest, California, developed an innovative extracorporeal platform technology for devices replacing functions of human organs such as kidneys, including home and hospital renal replacement therapy systems, ultrafiltration devices, and a wearable artificial kidney. Its core offerings encompassed prototype systems applying modern electronics and engineering to reduce size, cost, and power needs of conventional extracorporeal therapies like dialysis; the company targeted healthcare markets in the United States with no current active operations or geographic expansions beyond domestic focus. In December 2009, Xcorporeal signed an asset purchase agreement with National Quality Care, Inc., a Fresenius Medical Care North America affiliate, for substantially all assets including supersorbent dialysis technology, granting back a perpetual worldwide license option for non-renal healthcare uses following regulatory approval; this transaction maximized shareholder value amid strategic reviews of mergers, financing, and independence, effectively ceasing development activities thereafter. No further partnerships, acquisitions, product launches, funding, or operational changes have occurred since the 2010 liquidation initiation, with the entity maintaining a minimal market capitalization and no analyst coverage or revenue generation.